Braftovi (encorafenib capsules − Array) — Cigna

Initial criteria

• Patient age ≥ 18 years
• Patient has unresectable, advanced, or metastatic melanoma
• Patient has BRAF V600 mutation-positive disease

Approval duration

1 year